The osteoarthritis (OA) market was valued at USD 2.5 billion in 7MM (seven main markets) in 2021 and is predicted to develop to USD 3.8 billion in 2031 at a compound annual progress charge (CAGR) of 4.4%. The main progress drivers of the OA market through the forecast interval embody the launch of recent biologic therapies in addition to the launch of medicine with novel mechanisms of motion (MOA) and disease-modifying results. Two classes of recent therapies stand out: cell therapies and therapies with new MOAs, with new merchandise in every class projected to be launched between 2023 and 2025. These are projected to contribute considerably to the OA market gross sales in 2031, which accounting for 10% and 14.2% of 7MM gross sales, respectively.
The OA area has lengthy been dominated by giant pharmaceutical corporations resembling Bayer, Pfizerand Eli Lilly. That is largely because of the present requirements of care (SOC) in OA, which concentrate on symptom administration, and as such the market consists primarily of generic ache therapies, together with non-steroidal anti-inflammatory medicine (NSAIDs), opioids, antidepressants and intra-articular (IA) injections.
Nonetheless, the late pipeline is seeing new corporations enter the area, with intense competitors for affected person share driving innovation. As such, analgesics with revolutionary MOAs—together with anti-nerve progress components (anti-NGFs; fasinumab), an IA formulation of capsaicin (CNTX-4975), and new improved formulations of marketed therapies (X-0002)—proceed to be investigated. in scientific trials. In complete, eight new product launches are predicted within the OA market by 2031.
As well as, the OA market requires new DMOAD (disease-modifying OA drug) therapies to deal with the present unmet wants of OA sufferers. Because of this, a number of important therapies may be discovered within the present OA pipeline: the cell-based remedy Invossa, developed by Column tissue gene and Organogenesis Holdings‘s ReNu; in addition to Biosplice Therapeuticslorecivivint, a small molecule remedy.
The expansion of the OA market can be strongly pushed by the general rising affected person inhabitants, with a 12.3% improve within the variety of sufferers receiving remedy from 2021 to 2031. An ageing inhabitants is predicted to contribute to the general improve within the variety of sufferers and finally, the variety of sufferers receiving remedy. Nonetheless, probably the most notable issue limiting the expansion of the OA market is the shortage of progress in established ache market courses, and particularly the expansion of topical capsaicin (CAGR 0.7% within the US) and opioids (CAGR 1, 0% within the US).
Due to this fact, progress expectations for the general OA market (7MM) stay modest at a CAGR of 4.4% regardless of the launch of a number of new therapies through the forecast interval in addition to general progress within the affected person inhabitants.